<ul data-eligibleForWebStory="false"><li>Anthem Biosciences' IPO, entirely an offer-for-sale, is in its second day of trading with a 75% subscription rate at a price band of ₹540-570.</li><li>The IPO has a 35% reservation for retail investors, 50% for QIBs, and 15% for HNIs, with bids received for 3.21 crore shares against an offer of 4.40 crore, making it oversubscribed by 0.73 times.</li><li>Anthem Biosciences, an innovation-driven CRDMO with integrated drug discovery, development, and manufacturing operations, raised ₹1,016 crore from anchor investors prior to public subscription.</li><li>The company's anchor book saw participation from various investors, including Abu Dhabi Investment Authority, Government Pension Fund Global, and HDFC MF, with 1.78 crore equity shares allocated at ₹570 per share.</li><li>The eligibility of this news for web story generation is TRUE.</li></ul>

Anthem Biosciences IPO enters Day 2 with 75% subscription; IPO price band is ₹540-570

Discover more